Experimental drug tested to control protein leak in damaged kidneys

NCT ID NCT02682407

Terminated Disease control Sponsor: Omeros Corporation Source: ClinicalTrials.gov ↗

Summary

This study tested whether an experimental drug called OMS721 (narsoplimab) was safe and could reduce protein in the urine for adults with certain serious kidney diseases. It involved 31 participants with conditions like IgA nephropathy, lupus nephritis, and others, who received the drug by injection. The main goals were to check for side effects and see if the drug lowered protein levels, which is a sign of kidney damage.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Omeros Investigational Site

Denver, Colorado, 80230, United States
Omeros Investigational Site

Augusta, Georgia, 30909, United States
Omeros Investigational Site

Lawrenceville, Georgia, 30046, United States
Omeros Investigational Site

Evergreen Park, Illinois, 60805, United States
Omeros Investigational Site

Voorhees Township, New Jersey, 08043, United States
Omeros Investigational Site

Flushing, New York, 11355, United States
Omeros Investigational Site

San Antonio, Texas, 78215, United States
Omeros Investigational Site

Milwaukee, Wisconsin, 53226, United States
Omeros Investigational Site

Chai Wan, Hong Kong
Omeros Investigational Site

Hong Kong, Hong Kong
Omeros Investigational Site

Kowloon, Hong Kong
Omeros Investigational Site

Shatin, Hong Kong

Conditions

Explore the condition pages connected to this study.

C3G IGAN LN MN